Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.

Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z, Liang X.

BMC Cancer. 2016 Aug 2;16:578. doi: 10.1186/s12885-016-2640-3.

2.

South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy.

Prasad NR, Muthusamy G, Shanmugam M, Ambudkar SV.

Cancers (Basel). 2016 Mar 5;8(3). pii: E32. doi: 10.3390/cancers8030032. Review.

3.

High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer.

Barreiro-Alonso A, Lamas-Maceiras M, Rodríguez-Belmonte E, Vizoso-Vázquez Á, Quindós M, Cerdán ME.

Oxid Med Cell Longev. 2016;2016:5845061. doi: 10.1155/2016/5845061. Epub 2015 Nov 23. Review.

4.

Cellular Redox Status Regulates Emodin-Induced Radiosensitization of Nasopharyngeal Carcinoma Cells In Vitro and In Vivo.

Hou H, Li D, Cheng D, Li L, Liu Y, Zhou Y.

J Pharm (Cairo). 2013;2013:218297. doi: 10.1155/2013/218297. Epub 2013 Apr 16.

5.

Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation.

Ma J, Yang J, Wang C, Zhang N, Dong Y, Wang C, Wang Y, Lin X.

Biomed Res Int. 2014;2014:107671. doi: 10.1155/2014/107671. Epub 2014 Dec 14.

6.

A network pharmacology approach to understanding the mechanisms of action of traditional medicine: Bushenhuoxue formula for treatment of chronic kidney disease.

Shi SH, Cai YP, Cai XJ, Zheng XY, Cao DS, Ye FQ, Xiang Z.

PLoS One. 2014 Mar 5;9(3):e89123. doi: 10.1371/journal.pone.0089123. eCollection 2014.

7.

Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling.

Chen G, Qiu H, Ke SD, Hu SM, Yu SY, Zou SQ.

World J Gastroenterol. 2013 Apr 28;19(16):2481-91. doi: 10.3748/wjg.v19.i16.2481.

8.

The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels.

Franke K, Kettering M, Lange K, Kaiser WA, Hilger I.

Int J Nanomedicine. 2013;8:351-63. doi: 10.2147/IJN.S37465. Epub 2013 Jan 20.

9.

Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma.

Li XX, Dong Y, Wang W, Wang HL, Chen YY, Shi GY, Yi J, Wang J.

Stem Cells Dev. 2013 Feb 15;22(4):554-66. doi: 10.1089/scd.2011.0709. Epub 2012 Nov 7.

10.

The biphasic redox sensing of SENP3 accounts for the HIF-1 transcriptional activity shift by oxidative stress.

Wang Y, Yang J, Yang K, Cang H, Huang XZ, Li H, Yi J.

Acta Pharmacol Sin. 2012 Jul;33(7):953-63. doi: 10.1038/aps.2012.40. Epub 2012 Jun 11.

11.

Radiation, inflammation, and immune responses in cancer.

Multhoff G, Radons J.

Front Oncol. 2012 Jun 4;2:58. doi: 10.3389/fonc.2012.00058. eCollection 2012.

12.

Anti-cancer natural products isolated from chinese medicinal herbs.

Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J, Zhong Z, Xu Z, Dang Y, Guo J, Chen X, Wang Y.

Chin Med. 2011 Jul 22;6(1):27. doi: 10.1186/1749-8546-6-27.

13.

Proteomic analysis identified DJ-1 as a cisplatin resistant marker in non-small cell lung cancer.

Zeng HZ, Qu YQ, Zhang WJ, Xiu B, Deng AM, Liang AB.

Int J Mol Sci. 2011;12(6):3489-99. doi: 10.3390/ijms12063489. Epub 2011 Jun 1.

14.

Regulation of hypoxia inducible factor-1α expression by the alteration of redox status in HepG2 cells.

Jin WS, Kong ZL, Shen ZF, Jin YZ, Zhang WK, Chen GF.

J Exp Clin Cancer Res. 2011 May 19;30:61. doi: 10.1186/1756-9966-30-61.

15.

A novel Ca2+/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor.

Jung HJ, Kim JH, Shim JS, Kwon HJ.

J Biol Chem. 2010 Aug 13;285(33):25867-74. doi: 10.1074/jbc.M110.135632. Epub 2010 Jun 16.

16.

Species and gender differences affect the metabolism of emodin via glucuronidation.

Liu W, Tang L, Ye L, Cai Z, Xia B, Zhang J, Hu M, Liu Z.

AAPS J. 2010 Sep;12(3):424-36. doi: 10.1208/s12248-010-9200-6. Epub 2010 May 14.

17.

SENP3-mediated de-conjugation of SUMO2/3 from promyelocytic leukemia is correlated with accelerated cell proliferation under mild oxidative stress.

Han Y, Huang C, Sun X, Xiang B, Wang M, Yeh ET, Chen Y, Li H, Shi G, Cang H, Sun Y, Wang J, Wang W, Gao F, Yi J.

J Biol Chem. 2010 Apr 23;285(17):12906-15. doi: 10.1074/jbc.M109.071431. Epub 2010 Feb 24.

18.

SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation.

Huang C, Han Y, Wang Y, Sun X, Yan S, Yeh ET, Chen Y, Cang H, Li H, Shi G, Cheng J, Tang X, Yi J.

EMBO J. 2009 Sep 16;28(18):2748-62. doi: 10.1038/emboj.2009.210. Epub 2009 Aug 13.

Supplemental Content

Support Center